Senior analyst calls on Wall Street

Chevron Upgraded and Downgraded SolarEdge: Top Wall Street Analyst Calls

Chevron Upgraded and Downgraded SolarEdge: Top Wall Street Analyst Calls

The most talked about research and market moving calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 promotions:

  • Mizuho upgrade chevron (CVX) To buy from neutral with a target of $209, up from $205. Although higher commodity prices and an improving macro outlook have outperformed US oil and gas stocks, there is some secular tailwind to the energy sector that gives more confidence in cash generation over the long term, the company says. (read more)

  • UBS upgrade Stylish Dr. Pepper (KDP) To buy from neutral with a target of $42, up from $37. Shares are pricing in a decline in earnings strength over the next 12 months, but that’s misplaced, the company says, noting that an earnings reversal is starting to take shape amid sustained single-digit organic revenue growth and an improving outlook for the American coffee business. (read more)

  • Goldman Sachs upgrade Brixmore (BRX) To buy from neutral, with a $27 target. The company’s spreads and leasing provide “reliable growth,” while shares trade at a reduced multiple, the company says. (read more)

  • Upgrade Wolfe Research next decade (the next) To excel, Peer Perform at an $8 target. The Company believes the equity risk/reward is “extremely favorable” given the “limited commercial leverage” to obtain the final investment decision for Train No. 4 of the Rio Grande LNG. (read more)

  • Evercore ISI upgrade magnet (MGN) To outperform from In Line with a $14 price target, up from $11. The company is seeing exponential growth in revenue and EBITDA, the company says, and is in a more prominent position on the supply side of the advertising technology food chain. (read more)

Top 5 cuts:

  • BofA downgrade SolarEdge Technologies (SEDG) To neutral from Buy with a target of $181 down from $320. The company is “increasingly bearish” on the company’s component sales outlook in the medium term after channel checks with installers and distributors. (read more)

  • Argus lowered Magellan Midstream (millimeter) To sell from waiting after a “strong rally” in the stock. (read more)

  • lowered BTIG Marketa (MQ) On sale from neutral with a target price of $4. The stock didn’t move significantly after news of a four-year contract renewal with Squires (square foot) The company says the Cash implementation, likely attributable to the details of the agreement and the impact on net take-out rate, as well as ongoing problems with Marqeta’s non-consolidated revenue streams. (read more)

  • Mizuho lowered Petroleum Marathon (MPC) To neutral from Buy with a target of $161, up from $148. The company remains constructive in aerospace, particularly U.S. exploration and production stocks, but while refining margins are likely to be strong, it says the risk/reward for the group is skewed to the downside. (read more)

  • JPMorgan cut Chesapeake Energy (CHK) to an overweight neutral with a price target of $96, down from $97. The company cites the valuation, as the stock is currently among the most expensive of natural gas-focused exploration and production companies. (read more)

  • HC Wainwright lowered Gallera Therapeutics (GRTX) to Neutral from Buy with a target price of 30 cents, down from $6, after the company received a full response letter from the U.S. Food and Drug Administration (FDA) for the treatment of acute radiotherapy-induced mucositis in patients with head and neck cancer undergoing treatment. standard of care. (read more)

Top 5 initiatives:

  • Wells Fargo has started covering GE HealthCare (GEHC) With an overweight rating and a price target of $90. The company is well positioned to capitalize on its Alzheimer’s opportunity, the company tells investors in a research note. (read more)

  • Morgan Stanley has resumed coverage News Corp. (NWSA) With an overweight rating and a price target of $27.50. News Corp. continues to have a large component of cyclical media earnings, and while the past 12 months have been difficult, there are signs of stabilization in the earnings outlook, the company says. (read more)

  • JPMorgan has re-covered the viasat (VSAT) With a neutral rating and a price target of $35 after a period of restriction. The company is largely positive about the Inmarsat acquisition and the resulting shift toward higher-margin service revenues, but says recent complications with the launch of ViaSat-3 Americas “pose a meaningful headwind” for its fixed-broadband business. (read more)

  • Barclays started covering Fortria Holding Favorite With an equal weight rating and a target price of $29. The company notes that in the near term, the stock is a show story as investors may first want to see evidence of funding opportunities emerging in the top line as well as see margin improvements. (read more)

  • Guggenheim started covering Vera treatments (Vera) With a Buy rating and a $27 price target. The Company is optimistic about clinical, regulatory, and commercial progress in the Immune A Nephropathy market, and believes that atacicept Vera is well positioned to be a leader in this area. (read more)

Leave a Comment